Dan Groman - Jan 5, 2023 Form 4 Insider Report for Enfusion, Inc. (ENFN)

Role
Chief Technology Officer
Signature
/s/ Matthew Campobasso, as Attorney-in-Fact
Stock symbol
ENFN
Transactions as of
Jan 5, 2023
Transactions value $
$0
Form type
4
Date filed
1/9/2023, 04:39 PM
Previous filing
Nov 16, 2022
Next filing
Jan 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENFN Class A Common Stock Award $0 +5.65K +5.07% $0.00 117K Jan 5, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENFN Stock Option (Right to Buy) Award $0 +9.34K $0.00 9.34K Jan 5, 2023 Class A Common Stock 9.34K $11.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consist of restricted stock units ("RSUs") awarded pursuant to the Enfusion, Inc. 2021 Stock Option and Incentive Plan (the "Plan"). The RSUs will vest in full as follows: 1,884, 1,884 and 1,883 RSUs will vest on January 5, 2024, January 5, 2025 and January 5, 2026, respectively.
F2 These options were granted under the Plan and shall become exercisable as follows: 3,115, 3,114 and 3,114 on January 5, 2024, January 5, 2025 and January 5, 2026, respectively.

Remarks:

Exhibit 24 - Power of Attorney